{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T14:42:24Z","timestamp":1792334544418,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":89,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2022.100555","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:06:47Z","timestamp":1649074007000},"page":"100555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER\u2010medicare study"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5031-302X","authenticated-orcid":false,"given":"Robert S.","family":"Epstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrod","family":"Nelms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7638-0618","authenticated-orcid":false,"given":"Donald","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Girman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Chioda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2022.100555_bib0001","first-page":"1975","author":"Howlader","year":"2020","journal-title":"SEER Cancer Statistics Rev."},{"key":"10.1016\/j.ctarc.2022.100555_bib0002","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2022.100555_bib0003","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2022.100555_bib0004","first-page":"7s","article-title":"Executive summary: diagnosis and management of lung cancer","volume":"143","author":"Detterbeck","year":"2013","journal-title":"Am. College of Chest Physicians evidence-based Clin. Practice Guidelines, Chest"},{"key":"10.1016\/j.ctarc.2022.100555_bib0005","unstructured":"National Comprehensive Cancer Network, NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Small Cell Lung Cancer. Version 3. 2021. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1462, 2021 (Accessed March 24, 2021)."},{"key":"10.1016\/j.ctarc.2022.100555_bib0006","unstructured":"PDQ Adult Treatment Editorial Board, Small cell lung cancer treatment (PDQ\u00ae): health professional version, in: PDQ Cancer Information Summaries, National Cancer Institute (US), Bethesda (MD), 2002-2021."},{"key":"10.1016\/j.ctarc.2022.100555_bib0007","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2022.100555_bib0008","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0009","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2007.15.7545","article-title":"Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial","volume":"26","author":"Hermes","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0010","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.1995.13.10.2594","article-title":"Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study","volume":"13","author":"Loehrer","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0011","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2005.09.071","article-title":"Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: cancer and Leukemia Group B Trial 9732","volume":"23","author":"Niell","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0012","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/annonc\/mdq652","article-title":"Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group, A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer","volume":"22","author":"Schmittel","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0013","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"CONVERT Study Team, Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0014","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ijrobp.2017.11.025","article-title":"Radiation dose to the thoracic vertebral bodies is associated with acute hematologic toxicities in patients receiving concurrent chemoradiation for lung cancer: results of a single-center retrospective analysis","volume":"100","author":"Barney","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ctarc.2022.100555_bib0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cllc.2014.12.003","article-title":"Comorbidity in patients with small-cell lung cancer: trends and prognostic impact","volume":"16","author":"Aarts","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2022.100555_bib0016","first-page":"27","article-title":"Myelosuppression and its consequences in elderly patients with cancer","volume":"17","author":"Balducci","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ctarc.2022.100555_bib0017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","article-title":"Epidemiology of febrile neutropenia","volume":"1","author":"Lyman","year":"2003","journal-title":"Support. Cancer Ther."},{"key":"10.1016\/j.ctarc.2022.100555_bib0018","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/0897190014546108","article-title":"Antineoplastic agents and the associated myelosuppressive effects: a review","volume":"27","author":"Barreto","year":"2014","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.ctarc.2022.100555_bib0019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/IJCTM.S187569","article-title":"Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice","volume":"6","author":"Bryer","year":"2018","journal-title":"Int. J. Clin. Transfus. Med."},{"key":"10.1016\/j.ctarc.2022.100555_bib0020","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S1098-3597(06)80054-2","article-title":"Risks and consequences of chemotherapy-induced neutropenia","volume":"8","author":"Lyman","year":"2006","journal-title":"Clin. Cornerstone"},{"key":"10.1016\/j.ctarc.2022.100555_bib0021","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ctarc.2022.100555_bib0022","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/PPA.S292462","article-title":"Cancer patients' perspectives and experiences of chemotherapy-induced myelosuppression and its impact on daily life","volume":"15","author":"Epstein","year":"2021","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.ctarc.2022.100555_bib0023","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","article-title":"Patient burden and real-world management of chemotherapy-induced myelosuppression: results from an online survey of patients with solid tumors","volume":"37","author":"Epstein","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ctarc.2022.100555_bib0024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","article-title":"A review of relative dose intensity and survival in patients with metastatic solid tumors","volume":"93","author":"Havrilesky","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0025","doi-asserted-by":"crossref","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines","volume":"29","author":"Aapro","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0026","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","article-title":"NCCN guidelines insights: hematopoietic growth factors, version 1.2020","volume":"18","author":"Becker","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw"},{"key":"10.1016\/j.ctarc.2022.100555_bib0027","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0028","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3892\/mco.2015.693","article-title":"Lessons from the past: long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia","volume":"4","author":"Mountzios","year":"2016","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0029","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cnc.2017.04.002","article-title":"Adverse reactions to transfusion of blood products and best practices for prevention","volume":"29","author":"Frazier","year":"2017","journal-title":"Crit. Care Nurs. Clin. North Am."},{"key":"10.1016\/j.ctarc.2022.100555_bib0030","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1002\/cam4.2626","article-title":"Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: a SEER-Medicare study","volume":"8","author":"Shao","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctarc.2022.100555_bib0031","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/CMAR.S187317","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ctarc.2022.100555_bib0032","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s12325-019-01161-8","article-title":"Survival, chemotherapy treatments, and health care utilization among patients with advanced small cell lung cancer: an observational study","volume":"37","author":"He","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ctarc.2022.100555_bib0033","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/TCRM.S183216","article-title":"Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan","volume":"15","author":"DiBonaventura","year":"2019","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ctarc.2022.100555_bib0034","doi-asserted-by":"crossref","first-page":"Iv-3-18","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med. Care"},{"key":"10.1016\/j.ctarc.2022.100555_bib0035","first-page":"3","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.ctarc.2022.100555_bib0036","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clml.2016.01.006","article-title":"Mortality and vascular events among elderly patients with chronic myeloid leukemia: a retrospective analysis of linked SEER-Medicare data","volume":"16","author":"Lang","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ctarc.2022.100555_bib0037","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-15-B102","article-title":"NSCLC observations combining medical charts and administrative claims data","volume":"14","author":"Schwab","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ctarc.2022.100555_bib0038","series-title":"Visualization of Patient Electronic Records to Support Exploratory Analysis and Variable Derivation of Categorical Data","author":"Thomas","year":"2017"},{"key":"10.1016\/j.ctarc.2022.100555_bib0039","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/13696998.2021.2020570","article-title":"Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers","volume":"25","author":"Epstein","year":"2022","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ctarc.2022.100555_bib0040","first-page":"S1","article-title":"Real-world burden of myelosuppression among patients with extensive-stage small cell lung cancer treated in the community oncology setting","volume":"27","author":"Goldschmidt","year":"2021","journal-title":"J. Manag. Care Spec. Pharm"},{"key":"10.1016\/j.ctarc.2022.100555_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103335","article-title":"Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer","volume":"100","author":"Meng","year":"2019","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ctarc.2022.100555_bib0042","unstructured":"OPTUM, Determining lines of therapy (LOT) in oncology in claims databases. https:\/\/cdn-aem.optum.com\/content\/dam\/optum3\/optum\/en\/resources\/white-papers\/wf520768_guidelines-for-determining-lines-of-therapy.pdf, 2018 (Accessed June 2021)."},{"key":"10.1016\/j.ctarc.2022.100555_bib0043","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cncr.29674","article-title":"Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005","volume":"122","author":"Behera","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2022.100555_bib0044","first-page":"e13250","article-title":"Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer","volume":"29","author":"Cramer-van der Welle","year":"2020","journal-title":"Eur. J. Cancer Care (Engl.)"},{"key":"10.1016\/j.ctarc.2022.100555_bib0045","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/bjc.2013.812","article-title":"Treatment decisions and survival for people with small-cell lung cancer","volume":"110","author":"Powell","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2022.100555_bib0046","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.1998.16.10.3323","article-title":"Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer","volume":"16","author":"Murray","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0047","doi-asserted-by":"crossref","first-page":"vi99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Fr\u00fch","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0048","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"G1T28-02 Study Group, Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial","volume":"30","author":"Weiss","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0049","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/ijc.33453","article-title":"Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial","volume":"148","author":"Daniel","year":"2020","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.ctarc.2022.100555_bib0050","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","article-title":"Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study","volume":"38","author":"Hart","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ctarc.2022.100555_bib0051","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00044011-200727060-00002","article-title":"Economic burden of haematological adverse effects in cancer patients: a systematic review","volume":"27","author":"Liou","year":"2007","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ctarc.2022.100555_bib0052","first-page":"173","article-title":"Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system","volume":"8","author":"Rashid","year":"2016","journal-title":"Breast Cancer (Dove Med. Press)"},{"key":"10.1016\/j.ctarc.2022.100555_bib0053","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"ESMO guidelines committee, management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0054","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.18.02142","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update","volume":"37","author":"Bohlius","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100555_bib0055","first-page":"e10156","article-title":"Remote oncology care: review of current technology and future directions","volume":"12","author":"McGregor","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ctarc.2022.100555_bib0056","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","article-title":"Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies","volume":"22","author":"Weiss","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2022.100555_bib0057","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2014.02.018","article-title":"Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors","volume":"63","author":"Green","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.ctarc.2022.100555_bib0058","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0360-3016(94)00430-S","article-title":"Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy","volume":"31","author":"Mauch","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ctarc.2022.100555_bib0059","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijrobp.2015.09.022","article-title":"Thoracic vertebral body irradiation contributes to acute hematologic toxicity during chemoradiation therapy for non-small cell lung cancer","volume":"94","author":"Deek","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ctarc.2022.100555_bib0060","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1200\/JCO.1986.4.11.1615","article-title":"Effects of brain irradiation and chemotherapy on myelosuppression in small-cell lung cancer","volume":"4","author":"Lee","year":"1986","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:35:05Z","timestamp":1762842905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222000454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":60,"alternative-id":["S2468294222000454"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100555","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER\u2010medicare study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100555"}}